anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
People living with multiple chronic illnesses and an increasing need for acute care is a global health challenge, which questions the conventional ways of managing illness. A central issue is how medical practices can become more patient-centred and aligned with the everyday life of patients. Communicative strategies for eliciting the patient's goals and preferences are often proposed. In this article, we draw on ethnographic data from fieldwork conducted during 2019-2020 in health-care settings and among people living with multiple chronic illness(es) and repeated acute admissions in Denmark. Inspired by science and technology studies of chronic illness and care, we trace the enactments of illness and illness work in a patient trajectory marked by persistent symptoms and medical complexity. We analyse three medical encounters, and we show how 'tinkering' with clinical signs and utterances in each encounter constantly enacts new versions, shaping how the patient could and should live with his illness. We argue that specialised outpatient check-ups for these patients must provide space for continuous tinkering with the concrete effects of illness in everyday life.
The present invention relates to an orally taken pill for treating hepatopathy particularly hepatic ascites, which is prepared by mixing Chinese medicinal plants and jujube pulp and is coated by red bole outside, wherein the Chinese medicinal plants comprise astragalus root, stir-fried gansui root, spurge, saffron, bupleurum root, antelope horn, placenta, American ginseng and Chinese eaglewood. The orally taken pill has the functions of soothing the liver, promoting the circulation of qi, promoting urination to remove dampness, eliminating swelling, softening hard masses, invigorating the spleen to promote digestion, etc. The orally taken pill is mainly used for treating the diseases of hepatic ascites, hepatic cirrhosis, hepatosplenomegaly, hepatatrophia, etc. Through clinical verification, after the pill is taken for 2 to 3 times, ascites is reduced by 30 to 60% commonly by the intimation of type-B ultrasonic. The effective rate of the orally taken pill for treating hepatic ascites can reach 99%. The orally taken pill has the advantages of quick effect, obvious and lasting therapeutic effect, convenient use and no toxic or side effect.
The present invention relates to a mask pack containing a preservative-free cosmetic composition with a dead skin removal function and a biodegradable sheet having enhanced water retention, and a manufacturing method thereof. The safe preservative-free mask pack is manufactured by using a physical sterilization process to reduce skin irritation caused by chemical preservatives, and increase the amount of added functional raw materials. By using biodegradable fabric with increased water retention capacity, the absorption of preservative-free cosmetic composition can be increased and the drying time of the mask pack can be delayed. Also, the mask pack is environmentally friendly as the mask is naturally decomposed in the soil when discarded. The stratum corneum of the skin is decomposed by the mask with pomegranate extract applied thereto, and thus, skin is improved by accelerated nutrition and metabolism. The mask pack comprises: a preservative-free cosmetic composition; a biodegradable sheet having enhanced water retention; and a packing material for storing the preservative-free cosmetic composition and biodegradable sheet.
The invention discloses a formula of seven-ingredient health drug wine with effects of dispersing stasis and relieving syndrome of feeling fullness and distension in the upper abdomen. The formula is designed according to the principle of synergism of drugs and wine and comprises 80-100g of pinellia tuber, 80-100g of radix scutellariae, 50-70g of dry ginger, 50-70g of ginseng, 16-20g of coptis root, 28-32g of red dates and 50-70g of radix glycyrrhizae preparata. A preparation method of the seven-ingredient health drug wine comprises cleaning and airing the medical materials, grinding materials to obtain powder, putting the powder into a bag prepared from three layers of gauze through sewing, tightening the opening of the bag, immersing the bag in a jar with 200ml of liquor, sealing the jar, carrying out heating boiling through a mild fire for about 1h, after two weeks, opening the jar, taking out the drug bag and carrying out filtration to remove impurities to obtain the drinkable wine. An adult can drink about of 20ml of the warm wine before meal every day. The wine has effects of dispersing stasis and relieving syndrome of feeling fullness and distension in the upper abdomen, and harmonizing stomach for descending adverse qi, and can treat dysfunction of stomach, mutualeffect of chill and fever, hard glomus below the heart, nausea and qi rising, borborygmus and diarrhea, inappetence and fatigue.   .
Osteoporosis has become an important public health problem due to low bone mass, decreased bone strength and increased risk of fractures. Today, the measurement of quality of life plays an important role in the approach to diseases. Quality of Life Questionnaire of the European Foundation for Osteoporosis-41 (QUALEFFO-41) has been used for many years as a well-established and fully self-administered questionnaire. In the following years, a shorter and more practical version was needed because the QUALEFFO-41 contains many questions and takes a long time. For this reason, the questionnaire was updated in 2006 and the version of QUALEFFO-31 was made and the validity of the current questionnaire was shown. The aim of this study is to conduct the reliability and validity study of Turkish version of QUALEFFO-31 and to evaluate the power of the questionnaire to distinguish patients with osteoporosis.
Influenza virus infection leads to millions of cases of severe illnesses worldwide and up to an estimated 500.000 deaths annually. The potential for the sudden emergence of pandemic influenza strains represents an incessant threat on even a larger scale. seasonal influenza vaccination is the backbone of influenza management. However, antibodies generated by vaccination, most often do not effectively neutralize emergent strains due to the high mutation rate of the influenza viral genome. In addition, although vaccination is effective in up to 85% of healthy adults, only 40-60% of the elderly are able to mount an protective antibody response due to an agerelated decline in immune function (so-called immunoscenescence). As a result, the protective effects of influenza vaccination are limited, and strategies to improve host immune defenses against influenza virus infection per se, and following influenza vaccination, are highly warranted.

It is suggested that prior vaccination with Bacille Calmette-Guérin (BCG) could enhance resistance to other infectious diseases in addition to protection to tuberculosis (TBC) and, in mice, protection of prior BCGvaccination against influenza infection was demonstrated long ago. However, only recently substantial evidence for these nonspecific beneficial effects of BCG-vaccination in humans has been provided by several randomized clinical trials. Considering these potentiating effects of BCG-vaccination, it could be a viable strategy to improve efficacy of influenza vaccination, and/or enhance immune defenses against influenza virus infection per se. If so, this would have an enormous impact on clinical practice.
2-1-1 information specialists will deliver standard service, then ask a random number of callers per day if they would be willing to answer a few health questions as part of a new 2-1-1 service. Callers eligible to receive the invitation to screen for study eligibility will be: Missouri residents, calling for themselves, English-speaking, and not in acute crisis. Eligible smokers will then be asked if they are willing to share their contact information with a research team conducting a study to help smokers quit. Smokers who agree to share their contact information will be considered "enrolled". Trained 2-1-1 operators will record all recruitment screening data in a secure electronic database that is shared with research staff. Research staff will attempt to reach enrolled smokers by phone by the next business day.

Alere, through the Missouri Tobacco Quitline, will provide quitline services to smokers in all study conditions. Contact information and study group assignment for smokers will be provided to Alere via secure data transfer.
BACKGROUND: Cough is considered chronic when it lasts for >8 weeks. When no medical explanation can be found it is often called unexplained chronic cough (UCC), which may affect health-related quality of life (HRQOL). This study aimed to assesses the validity and reliability of the Swedish version of the Leicester Cough Questionnaire (LCQ-S) in patients with UCC.
METHODS: Seventy-six consecutively selected patients with UCC replied to: a local questionnaire; the LCQ-S; a Visual Analog Scale (VAS) for cough; the Swedish version of the Hull Airway Reflux Questionnaire (HARQ-S); and the Chemical Sensitivity Scale for Sensory Hyperreactivity (CSS-SHR). To evaluate the reproducibility of the LCQ-S, the VAS and LCQ-S were answered again after two to four weeks.
RESULTS: Seventy-four patients (17 men) answered the questionnaires at baseline. Concurrent validity for LCQ-S was regarded as moderate with the VAS for cough and HARQ-S. Internal consistency using Cronbach's alpha was high for the LCQ-S total score (0.92) and satisfactory for the LCQ-S domains (0.78-0.83). Reliability and reproducibility were analysed in 57 patients (14 men). Intra-class correlation for the LCQ-S total score and domains showed strong reliability (≥0.92), without any significant differences over time. The standard error of measurement and the smallest real difference were 1.26 and 3.49, respectively. The Bland-Altman plot showed no systematic change in the mean values.
CONCLUSIONS: The LCQ-S has good validity and reliability and can be used in clinical settings to evaluate HRQOL in Swedish-speaking adult patients with UCC.
The invention discloses a traditional Chinese medicine decoction for repelling verruca. The traditional Chinese medicine decoction comprises the following medicine materials by mass: 30g of rhizoma smilacis glabrae, 10g of coptis chinensis, 15g of golden cypress, 15g of edible tulip, 15g of polygonum cuspidatum, 20g of herba patriniae, 10g of peach kernel, 10g of the root of bidentate achyranthes, 15g of radix paeoniae alba, 10g of pangolin, 10g of phaseolus calcaratus, 15g of white atractylodes rhizome and 10g of liquorice, wherein the pangolin is firstly boiled for 30 minutes, and the other materials are subsequently boiled for 20 minutes. The dreg is eliminated and the liquid is orally taken for three times per day after meal for three days. An externally applied verruca washing liquid is prepared from 30g of radix sophorae flavescentis, 30g of caulis lonicerae, 20g of pericarpium zanthoxyli, 20g of herba portulacae, 30g of Chinese gall, 20g of dark plum, 20g of silkworm larva, 30g of golden cypress, 50g of cortex dictamni and 15g of alum; and the materials are boiled into liquid for washing the verruca once in the morning and evening. Brucea javanica non-deployed guaiazulene is used for external application. Anus condyloma acuminate is treated through oral taking and external application, patients suffer from less pain, the treating process is short, generally the disease can be treated within 3-5 days without reoccurrence, and the effect is good.
1532848 Purifying proteins P G S LINDROOS 19 Nov 1976 [11 Dec 1975] 48376/76 Heading C3H  A method for separating iron compounds from the protein in a hemoglobin solution, comprises adding to said solution an organic solvent comprising ethanol in an amount such that the total ethanol content in the solution is at least 40% by volume, adjusting the pH of the liquid to a value lower than 4À5, whereby iron compounds in the solution are agglomerated, and thereafter separating the agglomerated iron compounds from the solution. The solution may be adjusted to a pH value which is less than 4À5 but greater than 2À5. Preferably the pH-value of the solution after agglomeration of the iron compounds is, before or after their separation, raised and wherein any fraction of blood protein precipitated thereby, with iron compounds included therein or adsorbed thereonto, is separated from the mixture. Before or after the agglomeration of iron compounds a minor quantity of broth of blood cells may be added to the solution and any flaky material of fragments of cell membrane formed thereby, together with iron compounds adsorbed thereonto, is then separated from the mixture. The organic solvent preferably includes a minor proportion of glycerin or ethylene glycol or methanol or acetone or ethylacetate or propanol or isopropanol or butanol. The iron compounds may be separated from the solution by centrifuging or a cyclone process or filtering or ultrafiltering or sedimenting or adsorption on to  voluminous or solid material, and the protein may be recovered from the solution by precipitation or adsorption on to solid or voluminous material or ultrafiltering or evaporation of the solution or drying or concentration of the solution by means of freezing.  The ethanol content in the solution after the agglomeration of iron compounds may be increased before or after their isolation and the fraction of blood protein precipitated thereby, together with any iron compounds included therein or adsorbed thereonto, may then be separated from the mixture. Before addition of ethanol to the solution and lowering of the pH of the solution, the solution is preferably cooled to a temperature of between zero and -20‹ C. and wherein this temperature is maintained during the entire further treatment.
CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
Devices, methods, and kits for ocular drug delivery are described herein. An apparatus can include a housing, an energy storage member, a barrel, and a hub. The housing contains the energy storage member. A proximal end portion of the barrel is coupled to a distal end portion of the housing. The barrel is configured to contain medicament and includes at least a portion of a piston and an elastomeric member. The piston is configured to move the elastomeric member within the barrel in response to a force produced by the energy storage member. The hub is coupled to a distal end portion of the barrel. An inner surface of the hub defines a nozzle through which the medicament flows when the elastomeric member moves within the barrel. The nozzle and the energy storage member are collectively configured to produce a fluid jet to access a target location within an eye.
BACKGROUND AND OBJECTIVE: Barrett's esophagus (BE) is a precancerous condition that has the potential to develop into esophageal cancer (EC). Currently, there is a wide range of management options available for individuals at different pathological stages in Barrett's esophagus (BE). However, there is currently a lack of knowledge regarding their comparative efficacy. To address this gap, we conducted a network meta-analysis of published randomized controlled trials to examine the comparative effectiveness of all regimens.
METHODS: Data extracted from eligible randomized controlled trials were utilized in a Bayesian network meta-analysis to examine the relative effectiveness of BE's treatment regimens and determine their ranking in terms of efficacy. The ranking probability for each regimen was assessed using the surfaces under cumulative ranking values. The outcomes under investigation were complete ablation of BE, neoplastic progression of BE, and complete eradication of dysplasia.
RESULTS: We identified twenty-three RCT studies with a total of 1675 participants, and ten different interventions. Regarding complete ablation of non-dysplastic BE, the comparative effectiveness ranking indicated that argon plasma coagulation (APC) was the most effective regimen, with the highest SUCRA value, while surveillance and PPI/H2RA were found to be the least efficacious regimens. For complete ablation of BE with low-grade dysplasia, high-grade dysplasia, or esophageal cancer, photodynamic therapy (PDT) had the highest SUCRA value of 94.1%, indicating it as the best regimen. Additionally, for complete eradication of dysplasia, SUCRA plots showed a trend in ranking PDT as the highest with a SUCRA value of 91.2%. Finally, for neoplastic progression, radiofrequency ablation (RFA) and surgery were found to perform significantly better than surveillance. The risk of bias assessment revealed that 6 studies had an overall high risk of bias. However, meta-regression with risk of bias as a covariate did not indicate any influence on the model. In terms of the Confidence in Network Meta-Analysis evaluation, a high level of confidence was found for all treatment comparisons.
CONCLUSION: Endoscopic surveillance alone or PPI/H2RA alone may not be sufficient for managing BE, even in cases of non-dysplastic BE. However, APC has shown excellent efficacy in treating non-dysplastic BE. For cases of BE with low-grade dysplasia, high-grade dysplasia, or esophageal cancer, PDT may be the optimal intervention as it can induce regression of BE metaplasia and prevent future progression of BE to dysplasia and EC.
Malnutrition is a key factor in metabolic syndrome (MS) and sarcopenia, assessing the nutritional status of these patients is a pressing issue. The purpose of this study was to clarify sarcopenia and sarcopenic obesity in patients with MS based on nutritional status. This was a case-control study between MS/non-MS. Body composition was measured by dual-energy X-ray absorptiometry. Muscle function was assessed by handgrip strength, five times sit-to-stand test, gait speed test and short physical performance battery (SPPB). The Mini Nutritional Assessment (MNA) was performed to assess the nutritional status in the participants in this study. Overall, a total of 56 % and 13 % of participants suffered from possible sarcopenia and sarcopenia, respectively. There was a higher rate of possible sarcopenic obesity in the MS group than in the non-MS group (48·9 % v. 24·7 %, P < 0·01), and all the sarcopenia participants in the MS group had sarcopenic obesity. MNA score was significantly associated with sarcopenia status (P < 0·01). The MNA combined with body fat score showed better acceptable discrimination for detecting sarcopenic obesity and sarcopenia in MS (AUC = 0·70, 95 % CI 0·53, 0·86). In summary, there was a higher prevalence of possible sarcopenic obesity in MS, and all the MS patients with sarcopenia had sarcopenic obesity in the present study. We suggest that the MNA should be combined with body fat percentage to assess the nutritional status of MS participants, and it also serves as a good indicator for sarcopenia and sarcopenic obesity in MS.
Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have occurred in patients receiving penicillin. The incidence of anaphylactic shock in all penicillin-treated patients is between 0.015 and 0.04 percent. Anaphylactic shock resulting in death has occurred in approximately 0.002 percent of the patients treated. 

When oxacillin therapy is indicated, it should be initiated only after a comprehensive patient drug and allergy history has been obtained. If an allergic reaction occurs, oxacillin should be discontinued and appropriate therapy instituted. 

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Oxacillin for Injection, USP, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. 

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
The present invention provides an immune tbid gene, coded albumins thereof and an application of the immune tbid gene and the albumins thereof for preparing medicine for treating tumors. The present invention uses a single-chain antibody e23sFv gene capable of specifically recognizing and combining HER-2 positive tumor cells to be combined with a PEA trarsmembrane domain and an active truncating bid gene (tbid) to construct a novel molecule, namely the immune tbid gene with strong specificity, high activity, low immunogenicity and continuous killing for tumor cells. The present invention constructs a secreting immune target gene to express an effector molecule which can specifically identify and kill the tumor cells after secretion, and simultaneously, immunosurveillance is generated. Compared with other strategies, the gene treating strategy having the characteristics of cell immunity and humoral immunity has obvious advantages. The immune tbid gene constructed by the present invention has the advantages of security, high effectiveness and continuity. The present invention is desired to provide a new means for the targeted treatment of HER-2 positive tumors.
Despite recent new therapeutic options, allogeneic Stem Cell Transplantation remains the only curative option in patients with Myelofibrosis. Therefore, optimalization of this therapy remains a major challenge. Improvement of the clinical condition of these patients, decreasing spleen size can be accomplished by JAK2 inhibitor treatment and might improve SCT outcome. In addition, selective JAK2 inhibitors might modulate GvHD which can also add to improved SCT outcome. Also, decreasing the burden/activity of the disease before allo-SCT might also improve final disease response. The first, limited, clinical data of ruxolitinib treatment before allo-SCT show controversial effects on the outcome of SCT. Therefore, additional prospective clinical trials have to be done to establish the role of JAK2 inhibition before allogeneic SCT. Since ruxolitinib has considerable myelosuppressive effects which might limit the clinical use in some MF patients, other selective JAK2 inhibitors might be useful in this setting. Pacritinib, as a JAK2/FLT3 inhibitor, has a very potent JAK2 inhibitory activity without myelosuppressive effects and might therefore be more suitable than ruxolitinib. The major possible side effects are gastro-intestinal and can be managed with medication. In several studies, pacritinib has shown to be effective in decreasing spleen size and has shown to improve clinical condition of patients. Therefore, this compound seems promising in improving the outcome of allo-SCT. Although pacritinib causes no inhibition of JAK1 activity and therefore might have limited effects in decreasing inflammatory response, this might also be of benefit since a "withdrawal syndrome" as has been described after cessation of ruxolitinib is not to be expected.

With this trial, using pacritinib treatment before allo-SCT, the issue of improvement of SCT outcome will be investigated.
After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.